Tailored intermittent therapy of carcinoid

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Carcinoid tumors lack a standardized treatment protocol.
• Endogenous somatostatin rhythms are affected by lanreotide administration.
• Evaluating lanreotide's efficacy in metastatic carcinoid patients is crucial.

Purpose of the Study:

• To assess the effectiveness of lanreotide in managing the clinical progression of metastatic carcinoid disease.
• To investigate the impact of lanreotide on biochemical markers associated with carcinoid syndrome.
• To explore the relationship between endogenous somatostatin levels and treatment response.

Main Methods:

• Serum levels of somatostatin, 5-hydroxyindoleacetic acid (5-HIAA), neuron-specific enolase (NSE), and chromogranin A were measured in 43 carcinoid patients.
• Fifteen patients received intermittent lanreotide (30mg) injections every two weeks.
• Diurnal somatostatin excretion patterns were analyzed before and after treatment.

Main Results:

• Lanreotide therapy improved symptoms in 70-80% of patients with metastatic carcinoid syndrome.
• A significant decrease in 5-HIAA levels was observed post-lanreotide treatment.
• Elevated baseline somatostatin mesor in metastatic patients decreased after lanreotide, suggesting therapeutic impact.

Conclusions:

• Intermittent lanreotide therapy demonstrates efficacy in treating metastatic carcinoid tumors.
• Monitoring endogenous somatostatin levels may help determine optimal timing for lanreotide administration.
• The study observed a mean survival of 46.3 months for patients with metastatic carcinoid.